Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27920411 | 0.98 | EGFR (0.55) | EGFRKDRALKPARP1L3MBTL1 | |
| SCHEMBL1438135 | 0.88 | EGFR (0.57) | EGFRKDRALKPI4KAPI4K2B | |
| SCHEMBL28813506 | 0.80 | EGFR (0.56) | EGFRKDRALKPARP1L3MBTL1 | |
| SCHEMBL1192812 | 0.80 | ALK (0.60) | EGFRKDRALKPARP1L3MBTL1 | |
| SCHEMBL155127 | 0.80 | EGFR (0.56) | EGFRKDRALKPARP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2250729 | 0.79 | EGFR (0.55) | EGFRKDRALKPARP1L3MBTL1 | |
| SCHEMBL27537374 | 0.78 | PARP1 (0.54) | EGFRKDRALKPARP1L3MBTL1 | |
| SCHEMBL3974935 | 0.77 | ACHE (0.52) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL6202198 | 0.77 | NR4A2 (0.53) | EGFRKDRPARP1L3MBTL1XDH | |
| SCHEMBL2993744 | 0.76 | IRAK4 (0.53) | EGFRKDRALKPARP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340541-A | Preparation method of tocaintinib intermediate | 上海艾洋化学科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023195773-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | 보로노이 주식회사 | 2023-10-12 | — | — | WO | disclosed |
| CN-115340541-A | Preparation method of tocaintinib intermediate | 上海艾洋化学科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-114787150-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4013749-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | Black Diamond Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-105705493-B | Quinazoline derivative, preparation method, pharmaceutical composition and application thereof | 安润医药科技（苏州）有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-105705493-A | Quinazoline derivative, preparation method, pharmaceutical composition and application thereof | 安润医药科技（苏州）有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-101356171-A | N4-phenyl-quinazolin-4-amine derivatives and related compounds as ERBBI type receptor tyrosine kinase inhibitors for the treatment of proliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-01-28 | — | — | CN | disclosed |
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-4543356-A | Quinazoline derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-09-24 | — | — | US | disclosed |
| EP-0030156-B1 | QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-21 | — | — | EP | disclosed |
| US-4429126-A | ANTIASTHMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-01-31 | — | — | US | disclosed |
| US-4377580-A | ANTIALLERGENIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-22 | — | — | US | disclosed |
| EP-0030156-A1 | Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | EGFR 1395/4885KDR 2039/4885ALK 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.